MedTrace Logo

HepQuant to Predict Hepatic Encephalopathy After TIPS

NCT04664621 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-08-09

No results posted yet for this study

Summary

A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt through the liver to control complications of liver disease.

Conditions

  • Hepatic Encephalopathy
  • Cirrhosis, Liver

Interventions

DIAGNOSTIC_TEST

HepQuant

Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664621 on ClinicalTrials.gov